ZYME Overview

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Wall Street analysts forecast ZYME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYME is35.55 USD with a low forecast of 30.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Zymeworks Inc revenue for the last quarter amounts to 27.61M USD, increased 72.59

Zymeworks Inc. EPS for the last quarter amounts to -0.26 USD, decreased -33.33

Zymeworks Inc (ZYME) has 280 emplpoyees as of March 11 2026.

Today ZYME has the market capitalization of 1.89B USD.